Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study

Table 2 Global Mean eGFR decrease between the baseline and end-of-treatment

Global Mean eGFR Decrease between the baseline and EOT		p	Confidence Interval
Non TDF n = 152	5.40 ml/min/1.73m²	0.03	95%CI [(−7.44) -(−3.37)]
Non-boosted TDF n = 80	4.31 ml/min/1.73m²	< 0.01	95%CI [(−7.53) -(− 1.09)]
TDF + Boosted PI n = 50	2.02 ml/min/1.73m²	0.01	95%CI [(− 3.84) -(− 0.02)]

TDF tenofovir, PI protease inhibitor, Non TDF regimens without TDF, Non-boosted TDF regimens with TDF without boosted PI, TDF Boosted PI – regimens with TDF and boosted PI, EOT end of treatment

ISSN: 1471-2334